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Background: Urinary tract infections (UTIs) are one of the most common bacterial infections, and over 50% of
women will have a UTI during their lifetimes. Antibiotics are used for prophylaxis of recurrent UTIs but can lead to
emergence of drug-resistant bacteria. Therefore, it is reasonable to investigate nutritional strategies for prevention
of UTIs. Cranberry juices and supplements have been used for UTI prophylaxis, but with variable efficacy. Because
dried cranberries may contain a different spectrum of polyphenolics than juice, consuming berries may or may not
be more beneficial than juice in decreasing the incidence of UTIs in susceptible women. The primary objectives of
this study were to determine if consumption of sweetened, dried cranberries (SDC) decreases recurrent UTIs
and whether this intervention would alter the heterogeneity, virulence factor (VF) profiles, or numbers of intestinal
E. coli.
Methods: Twenty women with recurrent UTIs were enrolled in the trial and consumed one serving of SDC daily for
two weeks. Clinical efficacy was determined by two criteria, a decrease in the six-month UTI rates pre- and post-
consumption and increased time until the first UTI since beginning the study. Strain heterogeneity and virulence
factor profiles of intestinal E. coli isolated from rectal swabs were determined by DNA fingerprinting and muliplex
PCR, respectively. The numbers of intestinal E. coli eluted from rectal swabs pre- and post-consumption were also
quantified.
Results: Over one-half of the patients did not experience a UTI within six months of SDC consumption, and the
mean UTI rate per six months decreased significantly. Kaplan-Meier analysis of infection incidence in women
consuming SDC compared to patients in a previous control group showed a significant reduction in time until first
UTI within six months. The heterogeneity, VF profiles, and prevalence of intestinal E. coli strains were not
significantly different after cranberry consumption.
Conclusions: Results of this study indicate a beneficial effect from consuming SDC to reduce the number of UTIs in
susceptible women. Because there were no changes in the heterogeneity or VF profiles of E. coli, additional studies
are needed to determine the mechanism of action of SDC for reduction of UTIs.
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Urinary tract infections (UTIs) are one of the most com-
monly acquired bacterial infections. Over 50% of women
will have a UTI during their lifetimes, and approximately
25% of women will have at least one recurrence [1-3].
Recurrent UTIs (RUTI), defined as at least three epi-
sodes of UTI in the last 12 months or two episodes in
the last six months, can occur in susceptible women and
are a significant source of patient morbidity and health
care costs [4].
The treatment of RUTIs can vary depending upon the
physician and patient. The Infectious Disease Society of
America 2010 recommends a five-day course of nitrofur-
antoin as a first line treatment of acute, uncomplicated
cystitis; however, patients may be prescribed other an-
tibiotics as well [5]. Antibiotic prophylaxis can also be
initiated in patients with recurrent UTIs. One study
showed that 6 to 12 months of antimicrobial prophylaxis
was more effective than placebo in reducing the risk of
RUTIs in pre- and postmenopausal women [4]. In some
cases, patients may self-treat with post-coital antibiotics
if RUTIs are related to intercourse [6]. Unfortunately,
continuous and sporadic antibiotic use has the potential
to select for highly adaptive, multi-drug resistant orga-
nisms and can reduce the numbers of beneficial, com-
mensal bacteria in the intestinal flora. Also, long-term
use of nitrofurantoin, a common prophylactic antibiotic,
has been associated with health risks including pulmonary
toxicity, acute and chronic hepatic disease, neuropathy,
and anemia [7]. Further, there is no evidence-based rec-
ommendation of ideal prophylactic antibiotic, dosage, or
duration of treatment for RUTI [8]. Therefore, it is rea-
sonable to consider alternative, readily-available nutri-
tional supplements as prophylactic agents for RUTIs in
susceptible women.
Cranberry products have been studied for UTI preven-
tion and treatment. The most common products tested
include juices and pills or capsules containing cranberry
extracts or powdered fruit, both of which have demon-
strated conflicting evidence for prevention of RUTIs
[9-11]. One proposed mechanism of action is that one of
the primary compounds in cranberries, proanthocya-
nidins (PACs), inhibit P-fimbriated E. coli from adhering
to uroepithelial cells [12]. P-fimbriae mediate adherence
to uroepithelial cells via the P adhesin gene (papG),
which contains three unique allelic variants, with the
allele III variant being highly associated with acute
cystitis [13].
While previous studies have evaluated cranberry juice
and other cranberry products for UTI prophylaxis, none
have investigated whether consumption of dried cran-
berries have the potential to decrease the incidence of
RUTIs in susceptible women. Dried cranberries contain
high concentrations of polyphenols that may be active ininterfering with E. coli biologic or metabolic processes in
the intestine or inhibiting bacterial adherence to vaginal
or bladder epithelial cells. In addition, because E. coli is
the predominant uropathogen isolated from acute and
RUTIs in women and it is believed that the infecting
bacteria originate from the intestinal flora, the intestinal
tract may be an alternate site in which components of
the dried cranberries can interact with E. coli to reduce
infectivity [14,15].
The clinical study presented here investigated the effi-
cacy of consuming sweetened, dried cranberries (SDC)
to reduce UTI incidence in women with RUTIs. We
observed a reduction in the number of UTIs in the
six months following consumption of SDC daily for
two weeks. There were no significant changes in the
virulence profiles of intestinal E. coli during the study
period.
Materials and methods
Twenty women with a history of recurrent UTI, defined
as at least three UTIs in the past year (subjects with two
UTI’s in the past six months but not three in the past
year were also enrolled) provided informed consent at
the outpatient clinic of the University of Wisconsin
Hospital and Clinics, and were enrolled in the trial ap-
proved by the University of Wisconsin Health Sciences
Institutional Review Board. The number of subjects was
based on achieving a statistical power of at least 80% for
each of two parameters, infection-free status at the end
of the study, and changes in the E. coli strain diversity
measure. A six-month infection-free incidence of 60% in
20 UTI-susceptible women consuming SDC compared
to a 20% incidence in untreated women would provide
80% power with p = 0.05 using a two-tailed t-test. Simi-
larly, analysis of the diversity of E. coli strains isolated
from 20 subjects pre- and post-consumption would have
at least 80% power to detect a 0.66 standard deviation
shift in the Kullback Liebler (KL) diversity measure [16]
using a two-tailed t-test conducted at a significance level
of 0.05. The mean age of participants was 37, with a
range of 18 to 64, and the mean number of UTIs in the
past six months was 2.4 with a range of two to five.
Exclusion criteria included immune-compromising
diseases, co-morbidities, chronic inflammatory bowel
disease, diabetes, or cranberry allergy. Although target
enrollment for the study was 20 subjects, data from 3
subjects were removed from the analysis due to one
patient with exclusionary criteria realized after enroll-
ment, one patient with sample contamination, and
one patient with UTI contracted within one week of
study enrollment.
A two-week antibiotic washout period of non-
prophylactic antibiotics (i.e. full treatment course for
acute UTI) was required before beginning the study.
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however, were allowed to participate in the study, pro-
vided they met the inclusion criteria. A total of three
women who were taking prophylactic antibiotics were
enrolled in this study. The women in the study con-
sumed one serving (42 g) of SDC, provided by Ocean
Spray Cranberries Inc., each day for two weeks. Rectal
swabs were collected at the time of study entry to sam-
ple intestinal bacterial flora, and SDC consumption
began the following day. Rectal swabs were again col-
lected after two weeks of SDC consumption, and within
one day of final SDC consumption.
Clinical efficacy was determined by 1.) Comparison of
six-month UTI rates pre- and post-consumption, and 2.)
Kaplan-Meier analysis of the time until a patient’s first
UTI since beginning the study compared to a previous
control group with similar inclusion/exclusion criteria.
The six-month UTI rate was based on patient self-
reports and documentation of the total number of UTIs
in the year prior to the study and six-months since be-
ginning the study. Patients also reported the date of their
first UTI since the start of the study.
The presence of E. coli, Enterococcus sp., Klebsiella sp.,
S. Saprophyticus, S. aureus, and Proteus sp. were quanti-
fied as colony forming units (CFU) per ml from rectal
swab eluates on BBL™ CHROMagar Orientation media
(24hr growth at 37°C). Lactobacillus was quantified as
CFU/ml on deMan Rogosa Sharpe (MRS) Lactobacillus
agar and grown anaerobically for 72hr at 37°C. In ad-
dition, rectal swab eluates were streaked separately onto
eosin methylene blue agar to isolate E. coli, and the
last five colonies at the end of the streak area, includ-
ing any other morphologically distinct colonies, were
stored for further analysis. This method provides ≥97%
probability of capturing the predominant strain in the
sample [17].
E. coli strain heterogeneity was determined by
Diversilab™ DNA fingerprinting based on ERIC repeti-
tive PCR [18]. Five E. coli strains were isolated from
rectal swabs pre- and post-consumption, and the num-
ber of unique fingerprints was determined. The KL
diversity measure was used to determine changes in
intestinal E. coli heterogeneity pre- and post- SDC
consumption [16].
All isolates were confirmed as E. coli by amplification
of the glutamate decarboxylase (gad) gene in addition to
the colorimetric reaction on BBL™ CHROMagar Orien-
tation media [19]. Mulitplex PCR was used to determine
phylotype (A, B1, B2, or D) and the presence of six
pathogenicity islands (PAIs) and 15 VFs related to iron-
uptake, adhesion and toxicity [20-22]. The PAIs tested
were from E. coli J96 (IIJ96), E. coli CFT073 (ICFT, and
IICFT) and E. coli 536 (I536, II536, and IV536) [23]. The in-
dividual siderophore genes tested included fyuA, iroNE.coli, and iutA . The adhesion genes tested were sfa, papG
allele II/III, sfaS, and iha. The toxins included hlyA,
cnf1, pic, tsh, sat, and tosA, and other genes tested were
K1 and iss.
Two separate statistical analyses were used to evaluate
clinical efficacy. A two-tailed paired t-test and mean dif-
ferences with standard errors (SE) was used to deter-
mine significant differences in the six-month UTI rates
pre- and post-consumption. A log-rank test was used to
compare the time until first UTI between the current
study group and two placebo groups from previous cli-
nical trials. The two placebo groups from the previous
trials were pooled (p = 0.83).
Significant differences in the numbers (CFU/ml) of
bacteria present pre- and post-consumption were deter-
mined using the Wilcoxon matched pairs signed rank
test using log-transformed values to calculate geometric
means with 95% confidence intervals (CI), and the pres-
ence of VFs was expressed as percentages.Results
Clinical efficacy of SDC consumption in UTI-susceptible
women
There was a significant reduction in the incidence of
UTIs and time until first UTI recurrence in women con-
suming SDC, as determined by two separate statistical
analyses. First, the six-month UTI rate was compared
pre- and post-consumption. Nine of 17 (53%) patients
reported no UTIs within six months since beginning the
study, and the mean UTI rate per six months decreased
significantly from 2.4 to 1.1 (Figure 1, p = 0.004, mean
difference = 1.26 ± 0.38SE). Since three patients were
taking daily antibiotic prophylaxis which may affect
the results, the clinical efficacy was determined with
and without these patients. When these women were
excluded from analysis, the six-month UTI rate also
significantly decreased (p = 0.010, mean difference =
1.18 ± 0.39SE).
Second, Kaplan-Meier analysis compared the incidence
of UTIs in study patients to patients receiving a placebo
in two previous UTI vaccine trials [24]. Women in the
current and previous trials had equivalent UTI histories.
This analysis showed a significant reduction (p = 0.023)
in the acquisition of UTIs within six months for patients
consuming SDC (Figure 2). Fifty-three percent of wo-
men consuming SDC were uninfected compared to 20
percent of women receiving placebo who were unin-
fected six-months since beginning the study. When the
three women who were taking prophylactic antibiotics
were removed from the Kaplan-Meier analysis, the re-
sults were more statistically significant since the majority
of women taking prophylactic antibiotics still acquired
infections (p = 0.018).
Figure 1 Six-month UTI rates Pre- and Post- sweetened dried
cranberry consumption. In 17 patients, the mean pre- and post-
SDC consumption UTI rates were 2.4 and 1.1, respectively (p = 0.004).
The pre-consumption UTI rate is based on one half of the total
number of UTIs in the past year or the total UTIs in six months prior
to entering the study. Post-consumption six-month UTI rate is based
on the total number of UTIs reported six months since beginning
the study.
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post- SDC consumption
Based on the positive clinical implications of SDC
consumption, further microbiological analysis deter-
mined whether the intestinal flora was altered by SDCFigure 2 Increased time until first UTI following two-week
consumption of sweetened dried cranberries. Seventeen patients
consumed cranberries for the first two weeks of the study and were
followed for a total of six months. Twenty-four control patients were
given three doses of a placebo at one-month intervals in a previous
vaccine trial. Kaplan-Meier analysis of patients remaining infection-
free following SDC consumption compared to a previous control
had p = 0.023.consumption. There was a significant decrease (p = 0.040)
in the geometric mean of CFU/ml of E. coli isolated from
rectal swab eluates pre- and post-consumption (Figure 3).
There were no significant increases or decreases in En-
terococcus sp. (p = 0.315), Klebsiella sp. (p = 0.734), S.
Saprophyticus (p = 0.875), Lactobacillus sp. (p = 0.600) or
Unknown sp. (p = 0.508). S. aureus and Proteus sp. were
not isolated from any rectal swab eluates pre- or post-
consumption.
Heterogeneity of intestinal E. coli strains
To determine changes in E. coli heterogeneity pre-
and post-consumption within each patient, Diversilab™
DNA-fingerprint banding patterns for each rectal E. coli
strain were compared using KL clustering, and strains
that were ≥95% similar were considered identical and
those <95% similar were considered unique. The overall
diversity measure was calculated for each patient, and
those with both pre- and post-consumption rectal E. coli
present were analysed (n = 11). Based on the number of
unique E. coli strains isolated, the KL diversity measure
was calculated to determine any changes in heterogeneity
after SDC consumption. Seven of eleven patients (64%)
had no change in the diversity measure, 2/11 (18%) had
increased heterogeneity (A16 and A18), and 2/11 (18%)
had decreased heterogeneity post-consumption (A7, A11).
The overall mean diversity measure was 0.0080, which
indicates that there was no change in the heterogeneity of
E. coli after consumption of SDC (Table 1). Also, it is
important to note that 8/11 (72%) of the patients had at
least one dominant E. coli strain that was present before
and after SDC consumption.
The E. coli strains were further characterized by
phylotype and the prevalence of 15 VFs and 6 PAIs for
each unique strain. The VFs tested were those involved
in toxin production, adhesion, and iron regulation. Of
the phylotypes, VFs, and PAIs tested, only two of the
phylotypes, one iron-regulation gene (iutA), and one PAI
(ICFT) changed by more than ten percent after SDC con-
sumption. The least pathogenic phylotypes, A and B1,
increased by 8% and decreased by 14%, respectively, and
the more pathogenic phylotypes, B2 and D, decreased by
8% and increased by 11%, respectively. The proportion
of E. coli strains with iutA increased from 6/21 (29%) to
9/21 (45%) after SDC consumption and the proportion
of ICFT decreased from 10/21 (48%) to 7/21 (35%). All of
the other VFs and PAIs tested did not change by more
than ten percent.
Discussion
Here we report the results of a modified observational
clinical trial of two-week SDC consumption for the
prevention of UTIs in susceptible women. Using two
different methods to determine efficacy, consumption
Figure 3 Bacterial species present in rectal swab eluates pre- and post SDC consumption. Types of bacteria isolated from rectal swab
eluates at study entry and two weeks after consuming sweetened, dried cranberries. Bacterial cell counts are presented as geometric means
(CFU/ml) with 95% CI.
Table 1 Diversity measures of rectal E. coli strains




measure3Types2 Diversity Types Diversity
None
A1 5/0 0 5/0 0 0
A5 5/0 0 5/0 0 0
A8 5/0 0 5/0 0 0
A9 5/0 0 5/0 0 0
A13 5/0 0 5/0 0 0
A14 4/1 −0.2170 4/1 −0.2170 0
A19 5/0 0 5/0 0 0
Increase
A16 4/1 −0.2170 3/1/1 −0.4130 −0.196
A18 3/2 −0.2920 2/2/1 −0.4580 −0.166
Decrease
A7 2/2/1 −0.4580 4/1 −0.2170 0.241
A11 4/1 −0.2170 5/0 0 0.217
Total mean −0.1168 −0.1088 0.0080
1Diversity change indicates whether the number of unique strains increased,
decreased, or stayed the same after SDC consumption. Patient number 1 is
identified as A1, patient number 5 as A5, etc.
2Five E. coli strains were isolated from rectal swabs pre- and post-
consumption, and the number of unique fingerprints was determined using
Diversilab™ DNA-fingerprinting. Strains were compared using KL clustering,
and strains that were ≥95% similar were considered identical and those <95%
similar were considered unique. A type designated as 5/0 means that all 5
strains were ≥95% similar and there were no unique strains.
3When the DNA fingerprints of all five rectal E. coli isolates were the same,
the diversity measure was zero. As the number of unique fingerprints
increased, the diversity measure becomes an increasingly negative number.
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rence of UTIs in susceptible women. The significant de-
crease in six-month UTI rates per individual patient and
the comparison of UTI recurrences to a previous control
group of women with equivalent UTI histories provide
evidence of the potential prophylactic effect of SDC.
Based on the significant decrease in UTI incidence,
potential mechanisms of SDC action were investigated.
We examined whether the reduction in UTIs could be
accounted for by significant changes in the numbers or
prevalence of intestinal E. coli or other bacterial species
following SDC. E. coli was the only bacteria that showed
a significant decrease in overall numbers over the course
of the study. It is possible that polyphenols from SDC
blocked adherence of E. coli to the intestinal surface and
thus decreased their overall numbers, rather than exer-
ting a bactericidal effect. The lack of SDC toxicity is also
supported by the observation of no significant changes
in the numbers of the other intestinal bacteria surveyed.
It is thus likely that SDC are not affecting the growth of
commensal bacteria, which is contrary to what would
occur if patients were taking prophylactic antibiotics.
The lower numbers of intestinal E. coli, combined with
the lack of interference with other types of bacteria, may
provide a potential benefit since it produces no adverse
effects and results in decreased likelihood of UTI.
Although there were no changes in the heterogeneity
of intestinal E. coli strains after SDC consumption, we
questioned whether there were differences in the intes-
tinal E. coli phylotypes or virulence gene profiles after
SDC consumption. The proportion of E. coli with A and
D phylotypes was higher after SDC consumption than E.
coli with B1 and B2 phylotypes. Phylotypes A and B1 are
considered to be less uropathogenic than D and B2.
Thus, the increased presence of the A phylotype and
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cial; however, this does not explain the increased and de-
creased presence of E. coli with D and B1 phylotypes,
respectively. Although there were changes in the phy-
lotypes of E. coli pre- and post-consumption, there was
little change in the proportions of strains carrying VF
genes associated with UTI. The prevalence of only the
iutA and PAI ICFT VF genes in strains differed by more
than ten percent after SDC consumption. Overall, the
heterogeneity of E. coli and the presence of VFs did not
change as a result of SDC consumption, which suggests
that SDC do not directly influence the underlying make-
up of E. coli in the intestinal flora.
Because the significant reduction in the number of
UTIs following SDC consumption is most likely not re-
lated to reducing the prevalence or heterogeneity of
intestinal uropathogenic E. coli or other potential uro-
pathogens, alternative mechanisms whereby cranberry
phytochemicals could directly influence bacterial pheno-
types should be considered. One intriguing possibility is
that some components of cranberries may be able to
modulate expression of E. coli VF genes and reduce infec-
tivity and pathogenicity. Support for this concept comes
from several studies. Trans-cinnamaldehyde was shown to
decrease E. coli attachment to uroepithelial cells and to re-
duce cellular invasion in vitro by downregulating expres-
sion of the fimH gene coding for the adhesin of type 1 pili
[25]. Cinnamaldehyde and some of its derivatives were
also shown to reduce the virulence of Vibrio species by
decreasing the quorum sensing response [26]. It has also
been reported that compounds in crushed cranberries or
cranberry proanthocyanidins inhibited expression of the
fliC flagella structural gene in the CFT073 UPEC strain,
with subsequent loss of motility [27]. Resveratrol, which is
present in cranberries, decreased the pathogenicity of Pro-
teus mirabilis by inhibiting swarming as well as reduced
hemolysin production and urothelial cell invasion [28]. It
is possible that these, or other compounds found in cran-
berries could similarly decrease the virulence of intestinal
E. coli by gene modulation that reduces motility as well as
uroepithelial cell adherence and invasion, thereby redu-
cing uropathogenic E. coli persistence and infectivity in
the vagina and bladder.
Another potential mechanism to consider for the ob-
served clinical benefits of SDC consumption is that
cranberry phytochemicals may boost mucosal immunity
to uropathogens in the gastrointestinal tract. A recent
study has shown that cranberry proanthocyanidins can
be used as an adjunct to increase intestinal sIgA levels in
mice receiving enteral nutrition [29]. A clinical investiga-
tion found that consuming a cranberry beverage for ten
weeks resulted in a five-fold increase in proliferation of
T cells ex vivo, a 30% increase in NK cell proliferation,
and a 20% reduction in IL-17 secretion, as well as asignificant reduction in cold and flu symptoms com-
pared to placebo [30]. Further studies on the immune
enhancing effects of SDC in vivo could define which
components of the intestinal immune system are
targeted by cranberry phytochemicals.
Although SDC consumption did not prevent UTIs in
every patient, none of the patients reported any adverse
effects. Therefore, it may be suggested that SDC be used
as a prophylactic supplement for patients with recurrent
UTIs, since the potential benefits greatly outweigh the
risks. A larger, randomized, placebo-controlled study is
needed to confirm that daily consumption of SDC is
beneficial in the reduction of recurrent UTIs.
One of the limitations of the efficacy assessment is the
comparison of patients consuming SDC in this study to
a control group from a previous study. We are con-
fident, however, that this comparison between groups is
applicable and informative even though it is not the
most appropriate comparison for rigorous statistical ana-
lysis. Because the women in the current trial and the
previous placebo-controlled study had equivalent UTI
histories and similar demographics, we would expect
women in both groups to acquire UTIs at the same rate
over a six-month period without treatment interventions.
Randomized, placebo-controlled studies are necessary to
further determine the efficacy of SDC consumption.
Conclusions
The results of this study indicate a potential beneficial
effect of consuming SDC in reducing the number of re-
current UTIs in susceptible women; however, the results
shown here are only preliminary and further studies are
necessary. Daily SDC consumption is an inexpensive
and readily available supplement to a woman’s diet and
may provide potential prophylactic effects. Despite the
observed clinical efficacy of SDC consumption, however,
the underlying mechanism of SDC is still unclear. Two-
week consumption of SDC reduces the overall numbers
of E. coli in the intestines but does not change the E. coli
strain heterogeneity or the presence of other bacterial
types. Future studies are needed to determine the under-
lying mechanism of SDC for reduction of UTIs in sus-
ceptible women.
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